Mitocon - Insieme per lo Studio e la Cura delle Malattie Mitocondriali ODV

What Mitocon - Insieme per lo Studio e la Cura delle Malattie Mitocondriali ODV does

Mitocon - Insieme per lo Studio e la Cura delle Malattie Mitocondriali ODV is an Italian voluntary organization (Organizzazione di Volontariato) founded in 2007 by parents of children affected by mitochondrial diseases, headquartered in Rome. It functions as Italy's reference patient-advocacy organization for rare mitochondrial conditions (MELAS, Leigh Syndrome, TK2d, LHON, and others), operating a Clinical Registry of Mitochondrial Patients with 2,024 registered patients as of 2025, and connecting patients, families, clinicians, researchers, and Italian referral centers through an integrated program portfolio. The portfolio spans patient support (MitoCampus residential program, Spazi Rari webinars, Help Line, Mito Storie testimonials, Mito Podcast), research support (Mito Conference with 15 editions, Mito Awards, Grant Mitocon, Next Generation Talents, Leigh Syndrome Roadmap Project, Genomit Project), and awareness campaigns (World Mitochondrial Disease Week, LightUp for Mito). The organization is a founding member of the International Mito Patients (IMP) network, which now spans 16 associations across 11 countries and 3 continents serving over 8,000 patients and families. It maintains a Scientific Committee of 16 international experts and has cumulatively allocated €2,526,000 to research as of 2025.

The business model is a non-profit donation-and-grant model with no equity or commercial revenue line. Income is drawn from individual donations (single, recurring, memorial, birthday campaigns), the Italian 5x1000 tax designation (CF: 97488070588), corporate donations, testamentary bequests, event-based fundraising (MicroMito), and modest conference fees from healthcare professionals (€200-€400 per attendee for CME-accredited events; patients and caregivers attend free). Services to patients and families are delivered free of charge. Distribution is multi-channel: a website and donation portal at sostieni.mitocon.it, email/newsletter, social media, webinars, an annual national conference, the MitoCampus residential event, and a national network of local support groups. Operationally, Mitocon is a small volunteer-governed entity (1-10 paid staff), which limits scaling while keeping program overhead low relative to funds deployed to research.

Name

Mitocon - Insieme per lo Studio e la Cura delle Malattie Mitocondriali ODV

Legal name

MITOCON – Insieme per lo studio e la cura delle malattie mitocondriali – Odv, Organizzazione di Volontariato

Website

https://mitocon.it

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Mitocon is an Italian voluntary patient organization founded in 2007 that supports patients and families affected by mitochondrial diseases, funds research, and operates a 2,024-patient clinical registry and the international IMP network of 16 associations across 11 countries.

Ownership category

akta.pro rank

Product category

Patient Advocacy Services

NAICS

Voluntary Health Organizations (813212)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Membership Organizations (8600)

akta.pro primary industry

Neurogenetics & Rare Neurologic Diseases (HLAKAIAO)

Keywords

• Mitochondrial disease research
• Patient advocacy services
• Rare disease support
• Clinical patient registry
• Medical education webinars

Headquarters

HQ city

Roma, RM

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Individual Donations: Mitocon receives donations from individuals including single donations, regular recurring donations, and memorial donations. The organization promotes various donation campaigns including birthday donations (Compleanni Solidali) and direct appeals.
2. 5x1000 Tax Designation: Italian taxpayers can designate 5x1000 of their tax return to Mitocon (Tax Code: 97488070588). This represents a significant public funding mechanism.
3. Corporate Donations: The organization receives donations from companies and businesses through structured corporate giving programs.
4. Testamentary Bequests: Mitocon accepts testamentary bequests (Lasciti Testamentari) as part of its planned giving programs.
5. Event-based Fundraising: Revenue generated from events including volunteer activities and specific fundraising initiatives like MicroMito projects.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels10 records

Core offering

Mitocon is an Italian non-profit voluntary organization (Organizzazione di Volontariato) that supports patients and families affected by mitochondrial diseases through patient support programs (Spazi Rari webinars, MitoCampus residential events, Help Line), funds scientific research through grants and awards, hosts the annual Mito Conference with CME credits, maintains a Clinical Registry of Mitochondrial Patients with over 2,000 registered patients, and runs awareness campaigns including the annual World Mitochondrial Disease Week.

Product overview

Mitocon is a patient organization (non-profit/voluntary organization) that does not offer a technology product but provides a comprehensive ecosystem of patient support programs, research initiatives, and awareness campaigns. The core offerings include patient support services (Spazi Rari webinars, MitoCampus residential program, Mito Storie testimonials, Mito Podcast), research support (Clinical Patient Registry, Mito Conference, Mito Awards, Grants, Next Generation Talents program), and awareness initiatives (World Mitochondrial Disease Week, LightUp for Mito campaign). Additional services include educational webinars with ECM credits, Help Line support, donation processing, and international networking through IMP.

Differentiator

Problem solved

Functional benefit

Brands

• MitoCampus: An annual event for patients and families with mitochondrial diseases, providing psychological support, activities, and community building.
• Mito Awards
• MitoCorner
• Mito Podcast
• Spazi Rari
• Next Generation Talents
• Progetto S.M.A.R.T.
• LightUp for Mito
• Volti e Voci della MELAS

Products and services

• Spazi Rari Webinars Virtual appointment program featuring webinars and experiential groups for patients with mitochondrial diseases, families, and caregivers to meet experts and share experiences.
• MitoCampus Annual residential multi-day program offering patients and families psychological support, therapeutic activities, and peer connection. Co-financed by Waldensian Church 8x1000 funds.
• Clinical Registry of Mitochondrial Patients A patient registry that aggregates clinical data from 2,024 mitochondrial disease patients (as of 2025) to support research and improve treatment opportunities.
• Mito Conference Annual national/international conference bringing together clinicians, researchers, and patients to discuss mitochondrial disease research and clinical advances, with CME credits for healthcare professionals.
• Grant Mitocon Research grants program supporting scientists and clinicians working on mitochondrial diseases.
• Next Generation Talents Program supporting early-career researchers in developing expertise in mitochondrial disease research.
• Help Line Telephone (+39 340 7569156) and email ([email protected]) support service connecting patients and families with Mitocon for information and assistance.
• Webinar/FAD ECM Courses Continuing medical education (ECM) webinars and distance learning courses for healthcare professionals on mitochondrial diseases.
• Mito Corner Information and support service providing resources for patients and families affected by mitochondrial diseases.
• Progetto S.M.A.R.T. Patient support project providing specific assistance to families affected by mitochondrial diseases.

Quantifiable outcome

• €2,526,000 allocated to research funding
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Nine partnerships are on record, tiered core and minor.

• KhondrioncoreStrategic or Co-development Partner · 20 April 2026Dutch biotech company developing sonlicromanol for mitochondrial disease. Mitocon participates as a patient organization in the Phase 3 KHENERFIN clinical trial for patients with m.3243A>G primary mitochondrial disease. The study evaluates efficacy on fatigue and muscle weakness in adults across Europe, UK, and US including Italy (IRCCS Istituto Neurologico Carlo Besta, Milan).
• The Lily FoundationminorStrategic or Co-development Partner · 17 April 2026UK-based mitochondrial disease patient organization that participated in the Consensus Meeting in the Netherlands (April 17-18, 2026) to develop a new definition of mitochondrial diseases. Mitocon collaborated on this international effort to update disease classification.
• UCB (pharmaceutical company)coreStrategic or Co-development Partner · 31 March 2026UCB developed KYGEVVI (doxecitine and doxribtimine), the first EU-approved drug for TK2d (approved March 31, 2026). Mitocon supported patient community involvement and advocates for patient access to the therapy in Italy. The drug received EMA PRIME designation and FDA approval.
• Ti Sento TherapeuticscoreStrategic or Co-development Partner · 30 September 2025Sponsor of the PRIZM international Phase 2b clinical trial evaluating zagociguat for MELAS syndrome. Mitocon is involved in patient recruitment and launched the 'Volti e Voci della Melas' awareness project. Trial sites include IRCCS Istituto Neurologico Carlo Besta (Milan), Fondazione Policlinico Gemelli (Rome), and University of Pisa.
• Fondazione TelethonminorStrategic or Co-development Partner · 1 January 2025Italian research foundation that promotes the 'Piacere di conoscerti' project offering associations opportunities to connect with researchers including meetings with Dr. Brunella Franco and Dr. Alessia Indrieri.
• International Mito Patients (IMP)coreStrategic or Co-development Partner · 1 January 2012IMP is an international network founded in 2012 that today brings together 16 patient associations across 11 countries and 3 continents, representing over 8,000 patients and families. Mitocon is a founding member and Piero Santantonio serves as IMP Ambassador.
• IRCCS Istituto Neurologico Carlo Besta (Milan)coreStrategic or Co-development PartnerItalian neurology research institute serving as a clinical trial site for the KHENERFIN trial (Khondrion) and PRIZM trial (Ti Sento Therapeutics) for MELAS. Dr. Costanza Lamperti is the principal investigator.
• Fondazione Policlinico Universitario A. Gemelli IRCCS (Rome)coreStrategic or Co-development PartnerMajor Roman hospital serving as a clinical trial site for the PRIZM trial. Prof. Serenella Servidei is the principal investigator.
• Università di PisacoreStrategic or Co-development PartnerUniversity of Pisa's Neurology Clinic, led by Prof. Michelangelo Mancuso, serves as a clinical trial site for the PRIZM MELAS trial. Prof. Mancuso supervised the Consensus Meeting article on mitochondrial disease definition.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• National Organization for Rare Disorders (NORD): US rare disease umbrella that aggregates patient organizations and operates a research grants program — a broader, incumbent peer to Mitocon's grantmaking and advocacy role.
• Muscular Dystrophy Association (MDA): Large US neuromuscular disease advocacy organization that funds research and supports patients across a broader disease portfolio that includes some mitochondrial conditions. Comparable operating model at much larger scale.
• Fondazione Telethon: Major Italian research foundation funding genetic and rare disease research, including mitochondrial disease work that Mitocon also supports. Comparable funding model (5x1000, donations) and a known partner ('Piacere di conoscerti' project), though much broader in scope.

Direct peers

• MitoCanada: Canadian mitochondrial disease patient organization focused on research funding, patient support, and advocacy — directly comparable in mission and programs to Mitocon.
• United Mitochondrial Disease Foundation (UMDF): The largest US-based patient advocacy organization for mitochondrial diseases, supporting research, education, and patient services. Highly comparable mission and operating model to Mitocon, though at significantly greater scale.
• The Lily Foundation: UK-based mitochondrial disease patient charity that, like Mitocon, supports patients/families, funds research, and advocates for new therapies. Mitocon and The Lily Foundation co-partnered on the April 2026 mitochondrial disease consensus meeting in the Netherlands.
• Mito Foundation: Australia's leading mitochondrial disease patient organization, funding research and providing family support. Comparable scope to Mitocon across research funding, patient services, and awareness.

Others

• International Mito Patients (IMP): International umbrella of 16 mitochondrial patient associations across 11 countries. Mitocon is a founding member; this is a peer network rather than a direct competitor, given shared mission and overlap of board leadership.
• EURORDIS – Rare Diseases Europe: European umbrella for rare disease patient organizations. Mitocon engages through IMP into broader European rare-disease policy and advocacy work.
• UNIAMO FIMR (Federazione Italiana Malattie Rare): Italian federation of rare disease patient associations. Adjacent peer operating in the same Italian rare-disease advocacy and policy ecosystem as Mitocon.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/mitocon
• YouTubeyoutube.com/@mitocon
• Facebookfacebook.com/Mitocon
• LinkedInlinkedin.com/company/mitocon-odv
• Instagraminstagram.com/mitocon

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mitocon - Insieme per lo Studio e la Cura delle Malattie Mitocondriali ODV